Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial

BACKGROUND: A safe and highly efficacious Escherichia coli (E. coli)-produced HPV 16/18 bivalent vaccine has been prequalified by the World Health Organization. Here, we conducted a single-center, open-label, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of the sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Kai, Bi, Zhao-Feng, Huang, Wei-Jin, Li, Ya-Fei, Zhang, Li, Yang, Chang-Lin, Jiang, Han-Min, Zang, Xia, Chen, Qi, Liu, Dong-Lin, Pan, Hong-Xing, Huang, Yue, Zheng, Feng-Zhu, Zhang, Qiu-Fen, Sun, Guang, Su, Ying-Ying, Huang, Shou-Jie, Pan, Hui-Rong, Wu, Ting, Hu, Yue-Mei, Zhang, Jun, Zhu, Feng-Cai, Xia, Ning-Shao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240382/
https://www.ncbi.nlm.nih.gov/pubmed/37283969
http://dx.doi.org/10.1016/j.lanwpc.2023.100731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240382/
https://www.ncbi.nlm.nih.gov/pubmed/37283969
http://dx.doi.org/10.1016/j.lanwpc.2023.100731

Ejemplares similares